Interstellar comet older than Sun & Early galaxy and cosmic reionisation - News (Jun 24, 2026)

A comet from beyond our Solar System just gave scientists chemical clues that it may be billions of years older than the Sun—and its “fingerprints” don’t look like anything we’ve seen around here. Welcome to The Automated Daily, top news edition. The podcast created by generative AI. I’m TrendTeller, and today is June 24th, 2026. In the next few minutes: two big astronomy finds, major public-health signals from the UK, a new way to test cancer drugs on miniature patient tumors, fresh friction in US–Iran diplomacy, and another jolt in the AI talent race.

Interstellar comet older than Sun

Let’s start in deep space. Astronomers using the James Webb Space Telescope tracked an interstellar visitor—Comet 3I/ATLAS—as it moved away from the Sun and warmed enough to bloom into a bright gas cloud. Webb measured unusual isotope ratios in the comet’s material, including deuterium levels far higher than what’s typical in comets from our own neighborhood. Researchers say that points to an origin in an extremely cold environment, and potentially a formation time 10 to 12 billion years ago—meaning this object could predate the Sun by billions of years. It’s a rare chance to sample another planetary system’s building blocks, and to test how “normal” our Solar System really is.

Early galaxy and cosmic reionisation

Another space result tackles a different mystery: how the early Universe turned transparent. Using the Hubble Space Telescope, scientists detected escaping, ionising ultraviolet light from a compact young galaxy called MXDFz4.4, seen just 1.4 billion years after the Big Bang—earlier than previously confirmed cases. The key idea is that intense bursts of star formation can punch holes through surrounding gas, letting high-energy light leak out. That matters because this kind of light is thought to have helped end the cosmic “fog” of neutral hydrogen during the era of reionisation. In plain terms: it’s a clearer picture of how the Universe went from murky to see-through.

NHS rollout delaying type 1 diabetes

In health news from the UK, England and Wales are set to offer teplizumab on the NHS after approval by the National Institute for Health and Care Excellence. It’s the first medicine shown to delay the onset of stage 3 type 1 diabetes in people who are already on the path to the disease but haven’t developed full symptoms yet—covering children from age eight and up. It’s not a cure, and it doesn’t erase the risk, but a delay of up to three years can be huge: fewer years of constant insulin management, and more time for families to prepare. The decision also puts a spotlight on early detection, because people can only benefit if they’re identified before symptoms begin.

HPV vaccine cuts cervical deaths

Another UK health story delivers an unusually direct scoreboard for prevention. A Lancet study looking at national mortality records in England found zero cervical cancer deaths among women aged 20 to 24 between 2020 and 2024. In the early 2000s, that same age range still saw deaths each year. The researchers compared what actually happened with estimates of what would likely have occurred without HPV vaccination, and they conclude the vaccine programme has already prevented a large number of deaths overall. The takeaway is straightforward: HPV vaccination isn’t just reducing diagnoses—it’s saving lives. But researchers and clinicians also warn that slipping vaccination uptake could slow, or even reverse, momentum toward eliminating cervical cancer as a major public-health problem.

AI-tracked tumor organoid drug tests

Now to cancer research, where speed and scale can make the difference between a promising idea and something that helps patients. Researchers at UCLA Health’s Jonsson Comprehensive Cancer Center built a platform that combines 3D bioprinting, fast label-free imaging, and AI to watch how patient-derived tumor organoids respond to drugs in real time. Organoids are tiny “mini-tumors” grown from a patient’s own cancer cells, and they often behave more like real tumors than older lab models. What’s new here is the ability to produce lots of organoids in multiwell formats and measure growth changes without dyes or destructive tests—then use AI to track responses organoid by organoid across thousands of samples. Why that’s interesting: tumors aren’t uniform, and rare drug-resistant pockets can hide in the averages. Tools that capture that variation could help researchers spot resistance earlier—and, eventually, help clinicians choose therapies based on how a patient’s cells actually react before treatment starts.

US-Iran talks and inspections dispute

A separate biology initiative is also leaning into the idea that what cells do to each other matters as much as what they do alone. A UCLA-led team, with collaborators at USC and Caltech, is calling for a “Billion Cell×Cell Project,” aiming to systematically measure how pairs of human cells influence one another across huge numbers of controlled experiments. The pitch is that single-cell atlases have taught us what cells are present, and spatial maps show where they sit—but it’s still hard to prove cause and effect in cell-to-cell conversations. If a large, shared dataset can capture those interactions at scale, it could sharpen research on diseases where communication breaks down, including cancer and fibrosis, and help train better computational models of tissues.

EU momentum for under-16 limits

Turning to geopolitics: US–Iran diplomacy is showing how quickly negotiations can wobble when the public messaging doesn’t match. After talks in Switzerland, US leaders suggested Iran had agreed to let international nuclear inspectors back in, but Tehran has pushed back, saying no new commitments have been made and that any engagement would follow existing internal procedures. Iran also signaled it won’t grant access to sites hit during last year’s short war, which had already driven inspectors out. Meanwhile, the US issued a temporary sanctions waiver that loosens parts of the embargo, and mediators say both sides are aiming for a 60-day roadmap toward a wider deal, including steps to reduce risks in the Strait of Hormuz. The big issue is credibility: inspection access is one of the simplest ways to test whether any agreement is real—and the conflicting statements show how politically delicate that remains.

Google talent shifts in AI race

Related to that, an analysis in Ireland’s press suggests Israeli Prime Minister Binyamin Netanyahu is taking political heat at home after pushing for a tougher, more military-first approach toward Iran—only to see President Donald Trump pivot toward an interim diplomatic arrangement. Critics argue the emerging framework doesn’t meet Israel’s demands on Iran’s broader capabilities and regional influence, while also risking sanctions relief for Tehran. With Israeli elections expected later this year, the episode is being framed as a test of Netanyahu’s strategy—and of how much room Israel has to maneuver when Washington’s priorities shift.

Mapping how human cells interact

In Europe, leaders are signaling that social media rules for minors may be heading toward a continent-wide approach. EU figures say the European Commission is preparing concrete proposals to restrict access for children under 16, arguing that a shared framework would be stronger than a patchwork of national bans. The details—especially around age verification and enforcement—are still to come, and the politics will be tricky because any plan needs broad buy-in across the bloc. But the direction of travel is clear: more pressure on platforms to prove who’s using their services, and more emphasis on protecting children from cyberbullying and harmful content.

Finally, in the AI industry, the talent tug-of-war is getting more visible. Two high-profile Google AI researchers are leaving within days of each other: Gemini co-lead Noam Shazeer is heading to OpenAI, and AlphaFold leader John Jumper is set to join Anthropic after a break. Investors noticed, with Alphabet shares dipping amid wider concerns about AI spending and whether Google can keep top researchers from jumping to rivals. These departures won’t rewrite Google’s products overnight, but they do reinforce a bigger story: frontier AI labs are competing not just on models, but on people—and the ability to turn research leadership into developer-friendly tools and reliable businesses.

That’s the briefing for June 24th, 2026. If one story stuck with you today—the ancient interstellar comet, the NHS move on delaying type 1 diabetes, or the EU’s push on kids’ social media access—share this episode with someone who’d want the quick update. I’m TrendTeller, and you’ve been listening to The Automated Daily, top news edition. Check back tomorrow for the next run-through of what happened, and why it matters.

Interstellar comet older than Sun & Early galaxy and cosmic reionisation - News (Jun 24, 2026)

Our Sponsors

Today's Top News Topics